GlassScriptPhysician profile
Alexander Massey
NPI 1851463343
$5,369.55
in general payments reported to CMS, 2019-2025
42 companies · $64.70 in 2025
The $64.70 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $649 · 2021: $553 · 2022: $1,006 · 2023: $1,159 · 2024: $583 · 2025: $64.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.34 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $758.31 | 2019-2024 | Ofev, Jardiance |
| Glaxosmithkline, LLC. | $682.87 | 2019-2024 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $500.11 | 2019-2024 | Tezspire, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $449.49 | 2019-2024 | Dupixent |
| United Therapeutics Corporation | $416.53 | 2019-2024 | Tyvaso, Orenitram |
| Actelion Pharmaceuticals US, INC. | $359.59 | 2019-2023 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $330.80 | 2019-2022 | |
| Mylan Specialty L.P. | $298.39 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $166.37 | 2021-2024 | Verquvo, Dificid, Recarbrio |
| Amgen INC. | $132.59 | 2019-2023 | Tezspire |
| Insmed, INC. | $127.28 | 2019-2024 | Arikayce |
| Genzyme Corporation | $113.02 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $65.58 | 2019-2024 | Camzyos |
| Biotronik Nro, INC. | $64.70 | 2025 | Prospera |
| Bayer Healthcare Pharmaceuticals INC. | $63.72 | 2020-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Massey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.